Peptide World

Find your peptides

Peptide News · Not clinically reviewed

FDA advisers vote to back BPC-157, TB-500 and four more peptides for compounding

July 25, 2026 · Peptide World Editorial Team
News reporting, not medical advice. News posts are editorial coverage of current events. They are not clinically reviewed and are separate from our evidence-graded guides. Peptide World does not sell peptides and nothing here is a recommendation to buy or use any compound.
  • On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted to recommend adding six peptides to the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax.
  • The votes were narrow, and one peptide, emideltide (DSIP), was rejected.
  • The vote is a recommendation, not a rule change. Nothing is legal to compound today that was not legal last month.

What happened

The Pharmacy Compounding Advisory Committee met on July 23 and 24 and, for the first time, reviewed a slate of research peptides that until now sat outside any legal compounding pathway. The committee recommended all six candidates on the agenda, most by one or two votes:

BPC-1578–6KPV8–6TB-5008–6MOTS-c7–5Epitalon7–4Semax8–5Emideltide (DSIP)rejected 6–7

FDA’s own reviewers were skeptical going in: briefing documents cited short, underpowered studies that they considered insufficient to establish safety and efficacy for the proposed uses. Committee members who voted yes generally argued the risks appear small; members who voted no worried about safety, effectiveness, and the signal that a listing sends. Reporting around the meeting also noted scrutiny of the committee’s recent reconstitution and potential conflicts of interest among new members.

What it means, and what it does not mean

A PCAC recommendation is advisory. Before any of these peptides can be legally compounded under Section 503A, the recommendation still needs to be adopted through the formal process, with sign-off at the level of the HHS Secretary. Until that happens, the legal status of BPC-157, TB-500, Epitalon and the others is exactly what it was before the meeting: not FDA-approved, and not on the list that permits pharmacy compounding.

It also does not change anything about the grey-market vials sold online as “research chemicals”. Those remain unapproved products outside any regulated supply chain, and the FDA has spent 2026 sending warning letters to exactly those sellers.

What happens next

The FDA is expected to review further peptides in coming meetings, and the six recommendations now move into the formal listing process with no fixed timeline. If a substance is ultimately added to the 503A list, licensed compounding pharmacies could prepare it with a prescription, which would be the first legal, regulated route for several of these compounds. We will cover each step as it becomes official.

Frequently asked questions

Is BPC-157 legal now?

Its status has not changed yet. The committee vote is a recommendation. BPC-157 remains unapproved and not legally compoundable until the FDA formally adds it to the 503A Bulks List.

Does this make peptides from online “research” shops safe?

No. The vote concerns licensed compounding pharmacies working from a future official list. Unregulated online vials are unaffected and remain outside any quality-controlled supply chain.

Which peptide was rejected?

Emideltide, better known as DSIP (delta sleep-inducing peptide), was voted down 6 to 7.

Go deeper: our evidence-graded guides

Sources

  1. FDA Advisory Committee Calendar: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
  2. AJMC: FDA Panel Backs 6 Peptides for Compounding
  3. ABC News: FDA advisers narrowly vote to add 6 peptides to a drug compounding list
  4. Health Affairs Forefront: FDA Advisory Committee’s Vote May Open A Drug-Compounding Back Door